# China NMPA Drug Inspection - Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd. - Cornus officinalis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-huadingtang-traditional-chinese-medicine-pieces-technology-co-ltd/42c759ca-0204-4c80-8a91-f8d6db0b3efc/
Source feed: China

> China NMPA drug inspection for Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd. published February 28, 2020. Drug: Cornus officinalis. The Shaanxi Provincial Drug Administration published Announcement No. 12 on February 28, 2020, regarding the results of 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Provincial Drug Administration Announcement No. 12 of 2020
- Company Name: Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd.
- Publication Date: 2020-02-28
- Drug Name: Cornus officinalis
- Inspection Finding: Non-compliant; non-compliant item: [Appearance]
- Action Taken: The relevant municipal (county, district) drug regulatory authorities have taken necessary control measures and are investigating and handling the matter in accordance with relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration published Announcement No. 12 on February 28, 2020, regarding the results of its second round of drug sampling inspections for the year. The inspection focused on ensuring public safety by testing the quality of various medicinal products across the province. Five batches of traditional Chinese medicines were found to be non-compliant with the 2015 Edition of the Chinese Pharmacopoeia (Parts I and IV), which serves as the governing regulatory framework. 

The identified manufacturers include Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd., Bozhou Jingwan Traditional Chinese Medicine Pieces Factory, Anhui Yaozhiyuan Traditional Chinese Medicine Pieces Co., Ltd., Anhui Runbang Traditional Chinese Medicine Pieces Co., Ltd., and Bozhou Gongyao Pieces Factory. The main violations involved failures in physical characteristics (appearance), failed purity inspections, and incorrect concentrations of active ingredients. 

A notable detail in the report is that three of the manufacturers denied producing the specific batches that failed inspection, suggesting potential issues with counterfeiting or supply chain integrity. Consequently, the Shaanxi Provincial Drug Administration has instructed local regulatory departments to implement immediate control measures on the non-compliant products. These authorities are currently conducting formal investigations and will proceed with legal actions against the responsible parties to maintain strict adherence to drug safety laws.

Company: https://www.globalkeysolutions.net/companies/anhui-huadingtang-traditional-chinese-medicine-pieces-technology-co-ltd/9a5288f9-7040-4a85-9c7a-131b6c44472c/